An Open-label, Dose Escalating Phase Ib Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of GLPG0187 in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2016
At a glance
- Drugs GLPG 0187 (Primary)
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Galapagos NV
- 20 Jan 2016 Results published in the Investigational New Drugs.
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2013 Enrolment of patients has been completed; based on positive results and following requests of the investigators, additional patients will be included in this study, according to a Galapagos media release.